Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Pirbright/Oxford COVID-19 vaccine shows 'promising results'
The candidate vaccine, RBD-SpyVLP, produced a strong antibody response in mice and pigs.
Candidate could be used as a booster for individuals primed with a different COVID-19 vaccine.

A new COVID-19 vaccine being developed by researchers at The Pirbright Institute and the University of Oxford has shown 'promising results' in early animal studies.

The candidate, named RBD-SpyVLP, was found to produce a strong antibody response in mice and pigs. Although the vaccine is not a competitor for the first round of vaccines, researchers hope that it will prove useful as a stand-alone vaccine, or a booster for individuals primed with a different COVID-19 vaccine. 

Oxford's RBD-SpyVLP vaccine contains part of the SARS-CoV-2 spike protein called the receptor-binding domain (RBD) - a range of protective neutralising antibodies that can bind in a way that blocks infection. The RBD is attached to a virus-like particle (VLP) that contains no genetic material using Oxford’s SpyTag/SpyCatcher technology, a kind of protein ‘superglue’ 

The scientists found that RBD-SpyVLP produces a strong neutralising antibody response. They also examined samples taken from the nose and mouth of vaccinated pigs and found SARS-CoV-2 specific antibodies were present. This a promising finding, given that antibodies at the site of entry for SARS-CoV-2 could be important for providing robust protection. 

Interestingly, the team found no difference in the magnitude of antibody response when comparing vaccine dose levels. This suggests that the smaller dose tested, which is the same as intended for human administration, may provide equal protection to larger doses or that even lower doses of the vaccine may be effective.

Pirbright’s pig model has previously been used to test Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine, which showed that two doses produced a stronger immune response in pigs than one. 

Pigs have similar immune, respiratory and physiological characteristics to humans, and can therefore provide vital knowledge about the response to candidate vaccines that can inform human clinical trials. This model has been shown to predict vaccine outcome in humans, particularly in influenza studies. 

Professor Simon Graham, who led the pig studies at Pirbright, said: “These results offer valuable insights into the kind of immune responses that the RBD-SpyVLP vaccine could trigger in humans. Further understanding the dose required to elicit a strong immune response is key for the progression of vaccine development and scaling up for manufacture.” 

Researchers also tested the stability of the vaccine and found that RBD-SpyVLP is highly resilient, stable at room temperature and can be freeze-dried without losing its power to immunise. These properties would reduce dependence on cold chains for transport and storage and facilitate global distribution.

The study, A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses, is published in the journal Nature Communications.

Become a member or log in to add this story to your CPD history

Vets to run marathon for World Animal Protection

News Story 1
 Two recently graduated veterinary surgeons will be running the London Marathon in April to raise money for the charity World Animal Protection.

Alex Bartlett and Maeve O'Neill plan to run the race together if they are given the same start times.

Dr O'Neill said: "You're always limited in what you can do to help animals, so it is nice to raise money for a charity that helps animals around the world."

Dr Bartlett added: "I have never run a marathon before and am excited to run my first one for such a good cause!"

Both Dr Bartlett and Dr O'Neill have fundraising pages online. 

Click here for more...
News Shorts
BSAVA releases new Guide to Procedures

The British Small Animal Veterinary Association (BSAVA) has published a new edition of its Guide to Procedures for Small Animal Practice.

It has added four new procedures; cystostomy tube placement, endotracheal intubation, point-of-care ultrasound and wet-to-dry dressings.

BSAVA says that it is an essential step-by-step guide to diagnostic and therapeutic procedures performed in practice. The textbook includes new images and illustrations, as well as high-definition videos for use prior to procedures.

Nick Bexfield and Julia Riggs, editors of the new edition, said: "We have built upon the success of the previous editions by responding to the feedback received from the BSAVA readership, and hope this new guide helps to further increase the confidence and accuracy with which these procedures are performed."

Print copies are available in the BSAVA store, with a digital version in the BSAVA library.